These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22611747)

  • 1. Subacute cutaneous lupus erythematosus: a case report of Polypodium leucotomos as an adjuvant therapy.
    Breithaupt AD; Jacob SE
    Cutis; 2012 Apr; 89(4):183-4. PubMed ID: 22611747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial.
    Ramírez-Bosca A; Zapater P; Betlloch I; Albero F; Martínez A; Díaz-Alperi J; Horga JF;
    Actas Dermosifiliogr; 2012 Sep; 103(7):599-607. PubMed ID: 22560125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesico-bullous subacute cutaneous lupus erythematosus--an uncommon entity successfully treated with dapsone and hydroxychloroquine.
    Pinto-Almeida T; Sanches M; Alves R; Selores M
    Dermatol Online J; 2012 Aug; 18(8):13. PubMed ID: 22948063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypodium leucotomos: a potential new photoprotective agent.
    Bhatia N
    Am J Clin Dermatol; 2015 Apr; 16(2):73-9. PubMed ID: 25666116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses.
    Caccialanza M; Recalcati S; Piccinno R
    G Ital Dermatol Venereol; 2011 Apr; 146(2):85-7. PubMed ID: 21505393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photoprotective activity of oral polypodium leucotomos extract in 25 patients with idiopathic photodermatoses.
    Caccialanza M; Percivalle S; Piccinno R; Brambilla R
    Photodermatol Photoimmunol Photomed; 2007 Feb; 23(1):46-7. PubMed ID: 17254039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
    Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?
    Chaudhry SI; Murphy LA; White IR
    Clin Exp Dermatol; 2005 Nov; 30(6):655-8. PubMed ID: 16197381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypodium Leucotomos--An Overview of Basic Investigative Findings.
    Berman B; Ellis C; Elmets C
    J Drugs Dermatol; 2016 Feb; 15(2):224-8. PubMed ID: 26885792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subacute cutaneous lupus erythematosus presenting as erythroderma.
    Kalavala M; Shah V; Blackford S
    Clin Exp Dermatol; 2007 Jul; 32(4):388-90. PubMed ID: 17459074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption.
    Tanew A; Radakovic S; Gonzalez S; Venturini M; Calzavara-Pinton P
    J Am Acad Dermatol; 2012 Jan; 66(1):58-62. PubMed ID: 21696853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights in the use of a Polypodium leucotomos extract as an oral and topical photoprotective agent.
    Gonzalez S; Gilaberte Y; Philips N
    Photochem Photobiol Sci; 2010 Apr; 9(4):559-63. PubMed ID: 20354651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
    Xu K; Zhang M; Yang S; Yu G; Zheng P; Qin X; Feng J
    BMC Neurol; 2023 Apr; 23(1):168. PubMed ID: 37101279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
    Suess A; Sticherling M
    Int J Dermatol; 2008 Jan; 47(1):83-6. PubMed ID: 18173611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The different faces of cutaneous lupus erythematosus.
    Renner R; Sticherling M
    G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous lupus erythematosus: issues in diagnosis and treatment.
    Walling HW; Sontheimer RD
    Am J Clin Dermatol; 2009; 10(6):365-81. PubMed ID: 19824738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subacute cutaneous lupus erythematosus on the lines of Blaschko.
    Röckmann H; Feller G; Schadendorf D; Goerdt S
    Eur J Dermatol; 2006; 16(3):302-6. PubMed ID: 16709500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.